NCT01928186View on ClinicalTrials.gov

FLT PET in Measuring Treatment Response in Patients With Newly Diagnosed Estrogen Receptor-Positive, HER2-Negative Stage I-III Breast Cancer

NACompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

July 20, 2015

Study Completion Date

July 20, 2015

Conditions
Estrogen Receptor PositiveHER2/Neu NegativeMale Breast CarcinomaStage IA Breast CancerStage IB Breast CancerStage IIA Breast CancerStage IIB Breast CancerStage IIIA Breast CancerStage IIIB Breast CancerStage IIIC Breast Cancer
Interventions
DRUG

Fluorothymidine F-18

Undergo FLT PET

PROCEDURE

Positron Emission Tomography

Undergo FLT PET

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Run-in (short pre-surgery course) of endocrine-targeted therapy

Patients undergo run-in (short pre-surgery course) of endocrine-targeted therapy with aromatase inhibitor between the two (baseline and repeat) FLT PET scans. This is not an experimental therapy. This is a standard of care therapy that patients will continue after surgery, when the study is completed.

Trial Locations (1)

98109

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University of Washington

OTHER

NCT01928186 - FLT PET in Measuring Treatment Response in Patients With Newly Diagnosed Estrogen Receptor-Positive, HER2-Negative Stage I-III Breast Cancer | Biotech Hunter | Biotech Hunter